[Federal Register Volume 69, Number 219 (Monday, November 15, 2004)]
[Notices]
[Pages 65610-65611]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-25279]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Infectious Clone of Human Parvovirus B19 and Methods of Use

Ning Zhi et al. (NHLBI).
U.S. Patent Application No. 10/887,770 filed 09 Jul 2004 (DHHS 
Reference No.E-178-2004/0-US-01 and corresponding Canadian patent 
application (DHHS Reference No. E-178-2004/0-CA-02).
Licensing Contact: Susan Ano; 301/435-5515; <a href="/cdn-cgi/l/email-protection#f697989985b69b979f9ad8989f9ed8919980"><span class="__cf_email__" data-cfemail="ec8d82839fac818d8580c2828584c28b839a">[email protected]</span></a>.

    This technology described in this patent application relates the 
first reported infectious human parvovirus B19 clone, methods of 
cloning the parvovirus B19 genome as well as other viral genomes that 
have secondary DNA structures that are unstable in bacterial cells. The 
infectious clone and methods of producing the same would be useful in 
producing infectious virus, which can in turn be used, among other 
things, to identify and develop therapeutic agents for treatment and/or 
prevention of human parvovirus B19 infections. The infectious 
parvovirus B19 clone is also available for licensing. Additional 
information about this invention can be found in Virology 2004, 318(1), 
142-152.

Immunogenic Compositions for Eradication of Latent HIV

Genoveffa Franchini et al. (NCI).
U.S. Provisional Application No. 60/536,467 filed 13 Jan 2004 (DHHS 
Reference No. E-072-2004/0-US-01); U.S. Provisional Application No. 60/
536,976 filed 16 Jan 2004 (DHHS Reference No. E-072-2004/1-US-01).
Licensing Contact: Susan Ano; 301/435-5515; <a href="/cdn-cgi/l/email-protection#debfb0b1ad9eb3bfb7b2f0b0b7b6f0b9b1a8"><span class="__cf_email__" data-cfemail="e687888995a68b878f8ac8888f8ec8818990">[email protected]</span></a>.

    HIV infects CD4+ cells and, after incorporation of the viral genome 
into the host genome, can either produce infectious virus or remain 
latent. HIV that is latent presents a challenge for complete removal of 
the virus in infected individuals and is becoming an increasingly 
important consideration in the identification of potential therapeutics 
or treatment regimens. This patent application describes immunogenic 
compositions based on inhibiting the function of p28<SUP>TEV</SUP> 
protein, the first protein expressed during HIV infection, for 
treatment of latent HIV infection. Specifically, these compositions 
include the p28<SUP>TEV</SUP> polypeptide, a polypeptide with 
significant sequence homology to p28<SUP>TEV</SUP>, or immunogenic 
fragments of these polypeptides. Additional compositions include 
antibodies and other compounds that act to inhibit p28<SUP>TEV</SUP> 
activity. This technology can also be utilized to detect latent HIV in 
biological samples. These compositions and methods offer a potential 
solution for complete virus eradication in therapeutic treatment of HIV 
infected individuals.

Accelerated Vaccination Strategies To Provide Protection Against Viral 
Infections

Gary J. Nabel et al. (NIAID).
U.S. Provisional Application No. 60/491,933 filed 01 Aug 2003 (DHHS 
Reference No. E-317-2003/0-US-01); PCT Application filed on 01 Aug 2004 
(DHHS Reference No. E-317-2003/0-PCT-02).
Licensing Contact: Susan Ano; 301/435-5515; <a href="/cdn-cgi/l/email-protection#bbdad5d4c8fbd6dad2d795d5d2d395dcd4cd"><span class="__cf_email__" data-cfemail="33525d5c40735e525a5f1d5d5a5b1d545c45">[email protected]</span></a>.

    The technology described in this patent application relates to 
recombinant viruses for use as vaccines. These viruses contain a single 
or plurality of sequences encoding antigens from pathogenic viruses

[[Page 65611]]

heterologous to the recombinant virus. The antigenic sequences from 
pathogens such as influenza, RSV, measles, HPV, Epstein-Barr, Lassa, 
Polio, West Nile, Dengue, HIV-1 and 2, HTLV, herpes simplex virus, 
hepatitis viruses A, B, C, D, and E, Marburg, Ebola, and SARS are 
inserted into non-essential regions of either replication-competent or 
replication-defective adenovirus, adeno-associated virus (AAV), SV40 
virus, herpes simplex virus, or vaccinia virus vectors that retain 
elements necessary for infectivity but are devoid of any pathogenic 
sequence elements. In these recombinant viruses, the antigenic 
sequences are operably linked to viral control elements. Thus, these 
recombinant viruses are capable of infecting a host and mounting an 
immune response specific to a given virus(es) without eliciting 
pathogenicity. In addition to the above, the technology also describes 
methods of accelerated pre-exposure or post-exposure vaccination 
comprising single-dose administration. The attractive features of this 
invention include the broad applicability of the recombinant viruses 
against a number of common pathogens and the potential of using them 
against other emergent infectious viruses; the ability of the vaccines 
to stimulate both cellular and humoral immune responses in humans and 
other hosts; and the ease of administration in single dose form via a 
number of routes. This technology is now available for licensing. Some 
fields of use may not be available.

    Dated: November 9, 2004.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 04-25279 Filed 11-12-04; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>